Canopy Growth Corp. (TSX: WEED) (NYSE: CGC) said that it has named Dr. Danial Schecter as director of global medical services.
Schecter is an expert in the clinical use of medical cannabis and is expected to use his experience to expand the company’s network of partner healthcare clinics and support doctors and patients.
Schecter will focus on educational and outreach activities, including establishing new mentorship opportunities, developing training modules and organizing advisory boards to assist healthcare providers in each jurisdiction that allows medical cannabis access, Canopy Growth said in a statement.
Additionally, Schecter will identify and support clinics partnered with Spectrum Cannabis to ensure they operate at the highest standards, according to the company.
“Dr. Schecter will leverage his extraordinary wealth of front-line clinical experience as we expand the Company’s medical cannabis practice into new jurisdictions,” said Dr. Mark Ware, Chief Medical Officer, Canopy Growth. “We look forward to working with him as we continue our efforts to educate physicians and other healthcare providers who are committed to ensuring patients get the access to medical cannabis they deserve.”
Prior to joining Canopy Growth, Schecter was the co-founder and executive director of Canabo Medical Clinics, the largest referral-only clinic network specializing in medical cannabis in Canada.
He trained thousands of physicians and pharmacists on how to help patients decide if cannabis was the appropriate treatment for their specific medical conditions.
Schecter holds a fellowship in Hospital Medicine and is an active hospitalist at the Royal Victoria Regional Health Centre in Barrie, Ontario. He is also a practicing family physician providing house calls to at-risk elderly and palliative care patients.
“Schecter’s experience as a patient-focused family physician and leader in the medical cannabis sector makes him a welcome addition to Canopy Growth’s team of healthcare professionals and industry experts. Their combined efforts will further the company’s mission to provide reliable, consistent medical cannabis products that will improve the lives of patients around the world,” Canopy Growth said in a press statement.
